The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Lilly/Boehringer Ingelheim's insulin glargine product will be available in a pre-filled pen and cartridges for a reusable pen. The marketing authorisation for the Alliance's insulin glargine ...

Soliqua 100/33 (insulin glargine/lixisenatide) is a prescription drug that’s used to treat type 2 diabetes. Soliqua 100/33 comes as a prefilled single-use pen for injecting the drug under your skin.

NovoFine Autocover 30G disposable safety needles were dispensed for patients enrolled in the pen group. If insulin glargine was prescribed, a vial was dispensed regardless of the treatment group ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml ... available at a therapy cost of Rs 1,850 per pen. "The inclusion of Soliqua to our comprehensive ...